Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 32.9165
- Book/Share -0.0779
- PB -2032.7648
- Debt/Equity -385.1421
- CurrentRatio 0.7358
- ROIC 0.1416
- MktCap 370853940800.0
- FreeCF/Share 10.2929
- PFCF 20.333
- PE 98.6988
- Debt/Assets 0.5138
- DivYield 0.0308
- ROE 1.4231
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ABBV | Piper Sandler | -- | Overweight | -- | $231 | Aug. 12, 2025 |
| Upgrade | ABBV | Daiwa Securities | Neutral | Outperform | -- | $214 | Aug. 7, 2025 |
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
| Resumed | ABBV | BofA Securities | -- | Neutral | -- | $191 | Dec. 10, 2024 |
| Downgrade | ABBV | Daiwa Securities | Outperform | Neutral | -- | $180 | Dec. 5, 2024 |
| Initiation | ABBV | Bernstein | -- | Market Perform | -- | $203 | Oct. 17, 2024 |
News
AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. (NYSE:ABBV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Executive VP & Chief Commercial Officer Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.
Read More
Calls of the Day: Abbvie, Vertex, Veeva and Vistra
Published: September 08, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee discuss the latest Calls of the Day.
Read More
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
Published: September 08, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
Read More
AbbVie Declares Quarterly Dividend
Published: September 05, 2025 by: PRNewsWire
Sentiment: Neutral
NORTH CHICAGO, Ill. , Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Read More
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
Read More
Investing in the Age of Longevity: Silver Economy Stocks in Focus
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Read More
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
Read More
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Best Dividend Aristocrats For September 2025
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 Aristocrats raising payouts in 2025 and an average growth rate of 5.14%, signaling continued income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return, has outperformed both NOBL and SPY in August.
Read More
What Is the Intent Behind AbbVie's Recent Acquisition Spree?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.
Read More
AbbVie: Plenty Of Positives
Published: August 26, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie has had a good August, with double digit MoM gains after seeing weakness for six months. Factors like an EU-US deal on pharmaceuticals, recent results, improved guidance, positive outcomes in using Rinvoq to treat alopecia and even the expansion of its neuroscience portfolio support ABBV. However, the recent acquisition of a depression treatment candidate can impact the earnings outlook at a time when its market multiples already look stretched.
Read More
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter's lead pipeline candidate, bretisilocin (GM-2505), a novel therapy being developed for treating major depressive disorder(MDD).
Read More
AbbVie Is A Top Biotech Pick
Published: August 25, 2025 by: Seeking Alpha
Sentiment: Positive
Q2 earnings results were strong for AbbVie as top line growth is at a historically high level and operating margin expanded due to SG&A efficiencies. The company's Rinvoq drug has new market potential and U.S. manufacturing plans are likely to help mitigate tariff headwinds successfully. EPS guidance for the full year was raised and consensus estimates also show that the outlook for AbbVie is a strong one.
Read More
AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion
Published: August 25, 2025 by: Reuters
Sentiment: Positive
AbbVie said on Monday it would buy privately held Gilgamesh Pharmaceuticals' treatment for major depressive disorder in a deal worth up to $1.2 billion.
Read More
AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.
Read More
ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.
Read More
AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie jumps 11.5% in a month on strong Q2 results, raised guidance and momentum from Skyrizi, Rinvoq and neuroscience growth.
Read More
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
My 3 Favorite Stocks to Buy Right Now
Published: August 10, 2025 by: The Motley Fool
Sentiment: Positive
Short-term market fluctuations can be stressful, there's no doubt about that. The good news is, long-term investors are in a better position to weather these storms.
Read More
Jim Cramer Says To Buy These 3 Dividend Stocks ASAP
Published: August 05, 2025 by: 24/7 Wall Street
Sentiment: Positive
Jim Cramer likes these dividend stocks for 2025. All three dividend stocks are solid financially and pay good yields.
Read More
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
The Big 3: ABBV, ETSY, VRT
Published: August 04, 2025 by: Schwab Network
Sentiment: Positive
Mike Shorr (@ProsperTradingAcademy) walks through a pair of stocks he sees set up for a swing breakout: AbbVie (ABBV) and Etsy Inc. (ETSY). For both, he demonstrates an example options trade using a call spread.
Read More
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.
Read More
AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. (NYSE:ABBV ) Q2 2025 Earnings Conference Call July 31, 2025 9:00 AM ET Company Participants Elizabeth Shea - Senior Vice President of Investor Relations Jeffrey Ryan Stewart - Executive VP & Chief Commercial Officer Robert A. Michael - CEO & Chairman of the Board Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Scott T.
Read More
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
Published: July 31, 2025 by: MarketBeat
Sentiment: Positive
AbbVie Inc. NYSE: ABBV stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 earnings report. The biopharmaceutical giant reported global net revenue of $15.42 billion, beating expectations for $14.93 billion.
Read More
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.
Read More
PCE Comes in Warmer Than Expected
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
PCE Comes in Warmer Than Expected.
Read More
Economy Heating Up on PCE for June
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.
Read More
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Robert A. Michael CPA
- Employees 55000